(Total Views: 877)
Posted On: 05/27/2021 7:08:12 AM
Post# of 155038
Here is the translation
Anvisa approved the registration of the drug enoxaparin sodium, indicated for thromboembolism and used in the treatment of covid-19. The information was disclosed by Biomm, which has, since April, the exclusivity of licensing, supply, distribution and commercialization in Brazil.
According to the company, the registration of the drug, with the trade name of Ghemaxan, was treated as a priority by Anvisa due to its use by patients with covid-19. Biomm will request the price authorization from the Medicines Market Regulation Chamber (Cimed).
Read the full story at Valorinvest.
Anvisa approved the registration of the drug enoxaparin sodium, indicated for thromboembolism and used in the treatment of covid-19. The information was disclosed by Biomm, which has, since April, the exclusivity of licensing, supply, distribution and commercialization in Brazil.
According to the company, the registration of the drug, with the trade name of Ghemaxan, was treated as a priority by Anvisa due to its use by patients with covid-19. Biomm will request the price authorization from the Medicines Market Regulation Chamber (Cimed).
Read the full story at Valorinvest.
(1)
(0)
